Key transaction details
Jack Anders, chief financial officer of Revolution Medicines, Inc. (NASDAQ:RVMD), sold 2,753 shares of the company's common stock on March 17, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $99.4804 apiece, producing total proceeds of $273,869.
The filing shows the sale was executed under a pre-arranged Rule 10b5-1 trading plan that Anders adopted on May 31, 2023. The plan was established to address tax obligations arising when restricted stock units vest.
Ownership after the sale
Following the disposition, Anders directly holds 125,512 shares of Revolution Medicines. That figure includes 56,600 restricted stock units that remain part of his holdings.
Share price context
The transaction comes as RVMD shares trade near the stock's 52-week high of $124.49, after a reported 156% increase in the past 12 months. InvestingPro analysis noted that the stock is trading near its Fair Value and indicated there are 12 additional ProTips available for subscribers seeking deeper signals about the company's financial positioning.
Recent operating and financial developments
Revolution Medicines reported fourth-quarter 2025 results showing a loss per share of $1.86, wider than the consensus estimate loss of $1.58. The company attributed the shortfall in part to research and development expenses that exceeded expectations by $21.1 million, together with higher selling, general, and administrative costs.
Management reiterated its focus on advancing clinical programs in pancreatic cancer and non-small cell lung cancer, noting the support of a strategic partnership with Royalty Pharma. At quarter end, the company reported $2.03 billion in cash and investments on the balance sheet.
Analyst activity
Recent analyst moves reflect a range of outlooks. UBS initiated coverage with a Buy rating, citing the potential of Revolution's RAS inhibitors in treating various cancers. Piper Sandler raised its price target to $120 and maintained an Overweight rating. Needham trimmed assumptions to set a $145 price target while maintaining a Buy rating despite increased costs. Wells Fargo increased its price target to $144, expressing confidence in the company’s trajectory toward a pivotal readout in 2026.
This article presents the facts of the insider transaction and recent corporate and analyst disclosures. It does not provide investment advice.